Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Down 79.0% in November

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 774,700 shares, a decrease of 79.0% from the October 31st total of 3,690,000 shares. Approximately 3.5% of the shares of the company are short sold. Based on an average daily volume of 15,910,000 shares, the short-interest ratio is presently 0.0 days.

Insiders Place Their Bets

In other news, insider Neal Flomenberg sold 1,078,600 shares of the company’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the completion of the transaction, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. This represents a 20.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 56.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. bought a new stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned approximately 0.13% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Stock Down 2.2 %

Shares of Tevogen Bio stock traded down $0.03 during trading on Wednesday, hitting $1.31. 615,608 shares of the stock were exchanged, compared to its average volume of 4,948,997. The stock’s fifty day moving average is $1.25 and its 200 day moving average is $0.89. Tevogen Bio has a 12 month low of $0.26 and a 12 month high of $21.09.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.